Medical University of South Carolina - Cancer Center Support Grant

南卡罗来纳医科大学 - 癌症中心支持补助金

• 批准号: 9012167
• 负责人: ANTHONY J ALBERG
• 金额: $ 3.4万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9012167
• 关键词: Academic Medical Centers; Address; Award; Biomedical Engineering; Biometry; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Immunology Science; Cells; Charge; Clinical; Clinical Trials; Communities; Coupling; Development; Diagnosis; Enrollment; Ensure; Extramural Activities; Funding; Goals; Head; Healthcare; Instruction; Leadership; Malignant Neoplasms; Medical; Minority; Mission; Molecular; Movement; NCI Center for Cancer Research; National Cancer Institute; Oncogenes; Patients; Regulation; Research; Resources; Rural Population; Scientist; Secure; Services; South Carolina; Technology; Therapeutic; Therapy Evaluation; Tissues; Translational Research; Translations; Underserved Population; Universities; anticancer research; authority; base; bench to bedside; biobank; cancer education; cellular imaging; college; drug discovery; innovation; interdisciplinary collaboration; medically underserved; molecular imaging; novel strategies; outreach; population based; programs; ranpirnase; rapid growth; research facility; treatment trial

The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation awarded in 2009 via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's leading academic medical center, MUSC is charged with building clinical, basic, translational, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in South Carolina. To accomplish this mission, the Director, Dr. Andrew S. Kraft, and the HCC senior leadership have established a robust, interdisciplinary base that now includes 122 cancer scientists from 5 MUSC colleges and 20 academic departments. Interdisciplinary, innovative research is driven through the organization of the HCC into four programs: Cancer Genes & Molecular Regulation, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by shared research resources, five of which are presented in this application: Lipidomics, Cell Evaluation & Therapy, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. The HCC also seeks CCSG support for its Clinical Trials Office which has spear-headed a dramatic 59% increase in accrual volume for interventional treatment trials over the last four years. Notably, 26% of patients enrolled onto interventional treatment trials in 2012 were minorities, representing a 45% increase in this project period. This has been promoted by HCC-led progressive outreach services and cancer education to South Carolinians, a largely rural population that includes some of the most medically underserved people in the US. Today, the HCC has $40.8M in annual total extramural research funding with $18.6M derived from the NCI, representing a 31% and 54% increase respectively since 2009. The HCC has successfully leveraged CCSG funding during the first project period and its NCI-designated Cancer Center status to continue the rapid growth of this Center. During the current project period the HCC supported 34 strategic recruitments to the Center. The opening of two state-of-the-art research facilities at MUSC, the Bioengineering and Drug Discovery Buildings, has resulted in an additional 66,156 ft of HCC research space, bringing the total amount of space on campus under the HCC authority to 270,174 ft. The HCC has invested $5.3M since 2009 to introduce cutting-edge technologies and has secured another $3.8M in institutional commitments to increase the range of available resources. These impressive developments ensure that HCC scientists will continue their exemplary track record in making significant contributions to the understanding of cancer biology while coupling these findings to the development of novel approaches to cancer control, diagnosis, and treatment.

南卡罗来纳州医科大学（MUSC）的霍林斯癌症中心（HCC）寻求更新其 2009年通过P30癌症中心支持补助金授予国家癌症研究所（NCI）称号 （CCSG）机制。作为南卡罗来纳州领先的学术医疗中心，MUSC负责建设 临床，基础，转化和以人口为基础的研究计划，解决国家的重大 医疗需求。HCC的使命是减少南卡罗来纳州的癌症负担。完成 这次使命，主任，安德鲁·S。卡夫和HCC高级领导层已经建立了一个强大的， 跨学科基地，现在包括122名癌症科学家从5个MUSC学院和20个学术 部门跨学科，创新研究是通过HCC的组织分为四个驱动 项目：癌症基因与分子调控，癌症免疫学，发育性癌症 治疗学和癌症控制。快速的发现和有效的翻译 研究得到共享研究资源的支持，本申请中介绍了其中五种资源： 脂质组学、细胞评估和治疗、细胞和分子成像、生物储存和组织分析，以及 生物统计学。HCC还寻求CCSG对其临床试验办公室的支持，该办公室已率先开展了一项 在过去的四年中，介入治疗试验的累积量急剧增加了59%。值得注意的是， 2012年，26%的参与介入治疗试验的患者是少数民族，占45%。 在这个项目期间增加。人道主义协调委员会领导的渐进式外联服务促进了这一点， 南卡罗来纳州的癌症教育，主要是农村人口，其中包括一些最医学 在美国，服务不足的人。今天，HCC每年有4080万美元的校外研究资金， 来自NCI的1860万美元，自2009年以来分别增长了31%和54%。HCC已 在第一个项目期间成功地利用了CCSG的资金， 继续保持本中心的快速发展。在本项目期间，总部合同委员会支助了34个 为中心进行战略性招聘。MUSC两个最先进的研究设施的开放， 生物工程和药物发现大楼，导致了额外的66,156英尺的HCC研究 空间，使总面积的空间在校园下HCC的权力，以270,174英尺。HCC已 自2009年以来投资530万美元引进尖端技术，并已获得另外380万美元， 增加可用资源范围的机构承诺。这些令人印象深刻的发展 确保HCC科学家将继续他们在做出重大贡献方面的模范记录， 对癌症生物学的理解，同时将这些发现与新方法的开发相结合， 癌症控制、诊断和治疗。